Találati lista | Tudóstér

001-es BibID:	BIBFORM034198
Első szerző:	Szántó János (onkológus szakorvos)
Cím:	Az előrehaladott emlőrák gyógyszeres kezelése / Szántó János
Dátum:	1995
Megjegyzések:	The treatment of clinically overt metastatic breast cancer, despite several treatment modalities (biological response modifiers, megatherapy with autologous bone marrow transplantation, growth factors, new agents, etc.) is in a static phase. In the decision making one has to consider the patients's age, her menstrual state, the metastatic site, previous adjuvant and/or postoperative treatment modalities. Roughly there are two treatment forms, the hormonal and the cytostatic ones. Planning chemotherapy one should consider the menstrual stage of the patient. If she is in premenopausal stage and in the low risk group she can be treated either with LHRH analogues or with tamoxifen. In postmenopausal stage the rist choice is tamoxifen. After progression beyond 3 months a nocel hormonal treatment e.g. gestagen can be delivered. If there is a progression in 3 months, the hormonal treatment should be changed to cytostatic combination. The average efficacy of endocrine therapy is 30 per cent. In patients with advanced breast cancer chemotherapy provides a response rate of 30 to 60 per cent, however no response in total survival can be obtained. New plant alkaloids and altered treatment forms will probably influence survival. Taking all these into consideration one has to decide on the quality of life of the breast cancer patient.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok magyar nyelvű folyóiratközlemény hazai lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Lege Artis Medicinae. - 5 : 3 (1995), p. 212-217. -
Borító:
Saját polcon: